| The Rosacea./ La
Rosacea. ***********************************
****** DATA-MEDICOS *********
*********************************
LA ROSACEA / THE ROSACEA
**************************************
***** DERMAGIC-EXPRESS No 14 ******
****** 06 NOVIEMBRE 1.998 *******
************************************
1.) EDITORIAL
-------------
Amigos del Cyber, DERMAGIC los saluda de nuevo, LA ROSACEA, o ACNE ROSACEA, es el tema que revisé en estos dias, EL METRONIDAZOL, sigue siendo una buena alternativa de tratamiento, ha sido sacado al mercado en crema al 1%, (NORITATE, Dermik Laboratories). Otra Casa, GenDerm tiene un producto, el NOVACET (Sulfacetamida sodica al 10% con azufre al 5% que demostro ser bastante util en esta patología. Laser, isotretinoina, clindamicina, tetraciclinas, son otras alternativas. Estas 32 REFERENCIAS nos ilustran el tema.
Amigos de la RED-DERMATOLOGICA, hasta una nueva oportunidad.
======================================================================
DERMAGIC/EXPRESS(14)
======================================================================
L A R O S A C E A / THE ROSACEA ======================================================================
1.) Rosaceous lymphedema: a rare variant of a common disorder.
2.) Comparison of the long-pulse dye (590-595 nm) and KTP (532 nm) lasers
in the treatment of facial and leg telangiectasias.
3.) Rhinophyma: treatment with CO2 laser.
4.) [Rosacea with ocular involvement in a child]
5.) Rosacea: recognition and management for the primary care provider.
6.) The significance of Demodex folliculorum density in rosacea.
7.) A study of the prevalence of Helicobacter pylori infection and other
markers of upper gastrointestinal tract disease in patients with rosacea.
8.) Inflammatory cytokines in the tears of patients with ocular rosacea.
9.) Rosacea: how to recognize and treat an age-related skin disease.
10.) Topical metronidazole maintains remissions of rosacea. JUNIO 1.998
11.) Effective sunscreen ingredients and cutaneous irritation in patients with rosacea.
12.) Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea.
13.) Ocular rosacea: patient characteristics and follow-up.
14.) Cutaneous angiosarcoma of the face: clinicopathologic and
immunohistochemical study of a case resembling rosacea clinically.
15.) A study on Demodex folliculorum in rosacea.
16.) A double-blind, multicenter clinical trial comparing efficacy of
once-daily metronidazole 1 percent cream to vehicle in patients with rosacea.
17.) The Demodex mite population in rosacea [see comments]
18.) Treatment of rosacea: topical clindamycin versus oral tetracycline.
19.) [Double-blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea]
20.) Oral spironolactone therapy in male patients with rosacea.
21.) Childhood rosacea.
22.) A clinical and histopathologic study of granulomatous rosacea.
23.) Flash lamp pumped dye laser for rosacea-associated telangiectasia and erythema.
24.) Topical metronidazole for severe and recalcitrant rosacea: a prospective open trial.
25.) An epidemiological study of rosacea.
26.) Isotretinoin treatment of rosacea.
27.) May Helicobacter pylori be important for dermatologists?
28.) Efficacy and safety of topical azelaic acid (20 percent cream): an overview of
results from European clinical trials and experimental reports. (rosacea and acne)
29.) Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with
doxycycline [see comments]
30.) [Dapsone in granulomatous rosacea]
Dapson bei granulomatoser Rosazea.
31.) ROSACEA EN LA WEB: Noritate Available For Treatment Of Rosacea
32.) ROSACEA EN LA WEB: Lotion Proven Safe, Effective For Rosacea
====================================================
1.) Rosaceous lymphedema: a rare variant of a common disorder.
====================================================
Author
Harvey DT; Fenske NA; Glass LF
Address
Division of Dermatology and Cutaneous Surgery, University of South
Florida College of
Medicine 33612, USA.
Source
Cutis, 61(5):321-4 1998 Jun
Abstract
Rosaceous lymphedema is considered to be a rare and disfiguring
variant of acne rosacea.
Cases remain difficult to treat and can challenge afflicted patients
both cosmetically and
psychologically. We describe an unusual presentation of rosaceous
lymphedema and review
the differential diagnosis of persistent facial edema.
====================================================
2.) Comparison of the long-pulse dye (590-595 nm) and KTP (532 nm) lasers
in the treatment of facial and leg telangiectasias.
====================================================
Author
West TB; Alster TS
Address
Washington Institute of Dermatologic Laser Surgery, Washington, DC, USA.
Source
Dermatol Surg, 24(2):221-6 1998 Feb
Abstract
BACKGROUND: Telangiectasias develop on the face secondary to genetic
predisposition,
chronic actinic damage, collagen vascular disease, topical steroid
application, and disorders
of vascular regulation including acne rosacea. Linear and "spider"
telangiectasias develop on
the legs, especially in women beginning in the second to third decade,
secondary to multiple
factors including genetic predisposition, gravity, pregnancy, and
trauma. OBJECTIVE: The
purpose of this investigation was to compare the 590- and 595-nm
long-pulse (1.5 msec)
dye laser and KTP (532 nm) laser in the treatment of facial and leg
telangiectasias.
RESULTS: For both facial and lower extremity telangiectasias, the
difference in improvement
ratings between the two lasers following both one and two treatment
sessions was statistically
significant. CONCLUSION: Both the flashlamp-pumped long-pulse dye
laser and the KTP
laser may play a role in the treatment of facial and leg
telangiectasias. However, when used to
treat vessels on the lower extremities, both of these laser systems
are probably best used in
conjunction with sclerotherapy of the larger "feeding" reticular
veins. While long-pulse dye
laser irradiation achieves superior vessel clearance, patients may
prefer multiple treatments
with the KTP laser due to its low side effect profile and decreased
associated pain.
====================================================
3.) Rhinophyma: treatment with CO2 laser.
====================================================
Author
Lomeo P; McDonald J; Finneman J
Address
Department of Otolaryngology--Head and Neck, Mercy/General Health
Partners,
Muskegon, Michigan, USA.
Source
Ear Nose Throat J, 76(10):740-3 1997 Oct
Abstract
Rhinophyma is an acne rosacea which primarily affects the midface of
elderly men, and
causes disfigurement as well as obstruction. There are numerous ways
of treating this
condition and, in our institution, a CO2 laser is the treatment of
choice.
====================================================
4.) [Rosacea with ocular involvement in a child]
====================================================
Author
Bourrat E; Rybojad M; Deplus S; Morel P
Address
Service de Dermatologie, H^opital Saint-Louis, Paris.
Source
Ann Dermatol Venereol, 123(10):664-5 1996
Abstract
INTRODUCTION: Rosacea ia an uncommon facial eruption in children. We
report a case
of rosacea associated with a specific episcleritis. CASE REPORT: A
10-year-old girl
consulted for an erythematous papular and pustular eruption of the mid
face of 1 month
duration. The child complained that she had had a red painful right
eye for 6 months. There
was no argument for acne, periorificial granulomatous dermititis or
for sarcoidosis. The
ophthalmological examination gave the diagnosis of ocular and
cutaneous rosacea. Oral
antibiotics followed by erythromycin gave favorable results for both
skin and ocular lesions.
DISCUSSION: Ocular involvement is a frequent complication of rosacea
in adults. It is
exceptional in children in whom rosacea is in itself rare. The
presence of blepharitis,
keratoconjunctivitis or episcleritis may suggest the diagnosis in a
child with a mid facial
eruption. As in the adult, skin and ocular rosacea responds well to
prolonged oral antibiotics.
The choice of the antibiotic depends on the age of the child. Cyclins
are not authorized in
children under the age of 8 years.
====================================================
5.) Rosacea: recognition and management for the primary care provider.
====================================================
Author
Chalmers DA
Address
Integrated Cardiovascular Therapeutics, Woodbury, N.Y., USA.
Source
Nurse Pract, 22(10):18, 23-8, 30 1997 Oct
Abstract
Rosacea is a common facial dermatitis that currently affects an
estimated 13 million
Americans. It is a chronic and progressive cutaneous vascular
disorder, primarily involving
the malar and nasal areas of the face. Rosacea is characterized by
flushing, erythema,
papules, pustules, telanglectasia, facial edema, ocular lesions, and,
in its most advanced and
severe form, rhinophyma. Ocular lesions are common, including mild
conjunctivitis, burning,
and grittiness. Blepharitis, the most common ocular manifestation, is
a nonulcerative condition
of the lid margins. Rosacea most commonly occurs between the ages of
30 to 60, and may
be seen in women experiencing hormonal changes associated with
menopause. Women are
more frequently affected than men; the most severe cases, however, are
seen in men. Fair
complexioned individuals of Northern European descent are most likely
to be at risk for
rosacea; most appear to be pre-disposed to flushing and blushing.
Alcohol, stress, spicy
foods, and extremes of temperature have all been implicated, but have
not been found to
actually cause rosacea. Early diagnosis by the primary care
practitioner, management with
systemic antibiotics such as tetracycline, and topical agents such as
metronidazole, in
conjunction with patient education and lifestyle modifications, can
achieve remission in most
instances.
====================================================
6.) The significance of Demodex folliculorum density in rosacea.
====================================================
Author
Erba¨gci Z; Ozg¨ozta¸si O
Address
Department of Dermatology, Faculty of Medicine, Gaziantep University,
Turkey.
Source
Int J Dermatol, 37(6):421-5 1998 Jun
Abstract
BACKGROUND: Demodex folliculorum has been reported in rosacea in a
number of
clinical studies. As the Demodex mite is also present in many healthy
individuals, it has been
suggested that the mite may have a pathogenic role only when it is
present in high densities.
Moreover, some authors have proposed that a mite density above 5/cm2
may be a criterion
for the diagnosis of inflammatory rosacea. In this study, the possible
role of D. folliculorum
and the importance of mite density in rosacea were investigated using
a skin surface biopsy
technique. METHODS: Thirty-eight patients with rosacea and 38
age-and-sex-matched
healthy subjects entered the study. With the skin surface biopsy
technique, we obtained
samples from three facial sites. We then determined the mite
positivities, the mean mite counts
in both study groups, the mean mite densities at each facial site and
in the rosacea subgroups,
and the mite densities above 5/cm2. RESULTS: The mean mite count in
the rosacea group
(6,684) was significantly higher than that in controls (2,868; p <
0.05). The cheek was the
most frequently and heavily infested facial region. Ten rosacea
patients and five normal
subjects had mite densities over 5/cm2; the difference was not
statistically significant (p >
0.05). CONCLUSIONS: Rosacea is a disease of multifactorial origin, and
individual
properties may modify the severity of the inflammatory response to
Demodex. We suggest
that a certain mite density is not an appropriate criterion in the
diagnosis of the disease;
nevertheless, large numbers of D. folliculorum may have an important
role in the pathogenesis
of rosacea, together with other triggering factors.
====================================================
7.) A study of the prevalence of Helicobacter pylori infection and other
markers of upper gastrointestinal tract disease in patients with rosacea.
====================================================
Author
Sharma VK; Lynn A; Kaminski M; Vasudeva R; Howden CW
Address
Department of Internal Medicine, University of South Carolina School
of Medicine,
Columbia, USA.
Source
Am J Gastroenterol, 93(2):220-2 1998 Feb
Abstract
OBJECTIVE: Recent reports have suggested that patients with rosacea, a
chronic
inflammatory skin disorder of unknown etiology, have an increased
prevalence of
Helicobacter pylori infection. However, no causal relation has been
identified. This study was
designed to determine the prevalence of H. pylori infection and upper
gastrointestinal
symptoms in rosacea patients and in subjects without chronic skin
disorders. METHODS:
Forty-five patients with rosacea and 43 healthy subjects underwent
serological testing for H.
pylori infection. Demographics, gastrointestinal symptoms, and
medication use were recorded
using a structured questionnaire. RESULTS: There was no significant
difference in the
seroprevalence of H. pylori infection between rosacea patients and
healthy subjects (26.7%
vs 34.9%; p = 0.40). Significantly more patients with rosacea
complained of indigestion
(66.7% vs 32.6%; p = 0.001) and used antacids (60% vs 32.6; p = 0.01).
There was no
significant difference in the prevalence of H. pylori infection
between symptomatic and
asymptomatic rosacea patients, or in those using antacids. There were
no differences in the
frequency of heartburn, history of peptic ulcer disease, family
history of peptic ulcer disease,
use of H2-receptor antagonists, or use of nonsteroidal
antiinflammatory drugs.
CONCLUSIONS: Patients with rosacea have similar rates of H. pylori
infection as healthy
subjects. Rosacea patients complain significantly more frequently of
"indigestion" and use
more antacids unrelated to H. pylori infection.
====================================================
8.) Inflammatory cytokines in the tears of patients with ocular rosacea.
====================================================
Author
Barton K; Monroy DC; Nava A; Pflugfelder SC
Address
Ocular Surface and Tear Center, Bascom Palmer Eye Institute,
University of Miami School
of Medicine, Florida, USA.
Source
Ophthalmology, 104(11):1868-74 1997 Nov
Abstract
OBJECTIVE: The purpose of the study is to compare tear fluid
concentrations of
interleukin-1alpha (IL-1alpha), tumor necrosis factor-alpha
(TNF-alpha), and epidermal
growth factor (EGF) in ocular rosacea with those in control subjects
and to examine the
relation between tear functions, such as production and clearance
rate, and the
concentrations of cytokines in tear fluid. PARTICIPANTS AND INTERVENTION:
Fourteen patients with severe meibomian gland disease, facial rosacea,
and symptoms of
ocular irritation were examined for ocular surface disease, tear
production, and tear clearance
rate (TCR). Twelve control subjects, frequency-matched for age, and 15
ideal normal
subjects with no ocular symptoms and normal tear function were
assessed using the same
parameters. Minimally stimulated tear samples (20 microl) were drawn
from each subject and
analyzed using a sandwich enzyme-linked immunosorbent assay to detect
IL-1alpha,
TNF-alpha, and EGF. RESULTS: Tear IL-1alpha concentration was
significantly higher in
patients with rosacea than in age-matched (P = 0.003) and ideal
control subjects (P <
0.001). Tumor necrosis factor-alpha was not detected in patients or
control subjects,
indicating levels of less than 10 pg/ml. Epidermal growth factor was
not significantly higher in
patients with rosacea than in age-matched control subjects. Tear
turnover LN(TCR) was
lower in patients with rosacea than in both age-matched (P = 0.048)
and ideal control
subjects (P = 0.002). Schirmer I scores were statistically lower in
patients with rosacea than
in ideal control subjects (P = 0.013), but not age-matched control
subjects.
Interleukin-1alpha was correlated inversely with LN(TCR) (r= -0.58, P
< 0.0001) and
Schirmer I (r = -0.39, P = 0.012). CONCLUSIONS: Concentrations of
IL-1alpha are
present in normal tears but are elevated in ocular rosacea, whereas
TNF-alpha is not present
in either case. The reduced tear turnover, LN(TCR), its inverse
correlation with IL-1alpha,
and the absence of TNF-alpha in the tears of these patients suggest
that the increased
concentration of IL-1alpha observed may be largely because of
clearance failure of cytokine
normally produced at the ocular surface.
====================================================
9.) Rosacea: how to recognize and treat an age-related skin disease.
====================================================
Author
Litt JZ
Address
Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Source
Geriatrics, 52(11):39-40, 42, 45-7 1997 Nov
Abstract
Rosacea is an age-related disorder of the central portion of the
facial skin whose peak onset
occurs in persons in their 40s and 50s. A chronic and progressive
condition of flare-ups and
remissions, rosacea can be disfiguring if left untreated. Rosacea can
be characterized as
having three stages. Target areas for all symptoms include the cheeks,
nose, chin, or
forehead. Rosacea resembles a number of other dermatologic conditions,
particularly acne
vulgaris. The combination of oral and topical antibiotic therapy
usually brings about remission.
The key is to recognize the early signs and clinical picture so that
accurate diagnosis can be
made and therapy and counseling instituted.
====================================================
10.) Topical metronidazole maintains remissions of rosacea.
====================================================
Author
Dahl MV; Katz HI; Krueger GG; Millikan LE; Odom RB; Parker F; Wolf JE
Jr; Aly R;
Bayles C; Reusser B; Weidner M; Coleman E; Patrignelli R; Tuley MR;
Baker MO;
Herndon JH Jr; Czernielewski JM
Address
Department of Dermatology, University of Minnesota, Minneapolis, USA.
Source
Arch Dermatol, 134(6):679-83 1998 Jun
Abstract
BACKGROUND: Rosacea is a chronic skin disease that requires long-term
therapy. Oral
antibiotics and topical metronidazole successfully treat rosacea.
Because long-term use of
systemic antibiotics carries risks for systemic complications and
adverse reactions, topical
treatments are preferred. OBJECTIVE: To determine if the use of
topical metronidazole gel
(Metrogel) could prevent relapse of moderate to severe rosacea.
DESIGN: A combination
of oral tetracycline and topical metronidazole gel was used to treat
113 subjects with
rosacea (open portion of the study). Successfully treated subjects (n
= 88) entered a
randomized, double-blind, placebo-controlled study applying either
0.75% topical
metronidazole gel (active agent) or topical metronidazole vehicle gel
(placebo) twice daily
(blinded portion of the study). SETTING: Subjects were enrolled at 6
separate sites in large
cities at sites associated with major medical centers. SUBJECTS: One
hundred thirteen
subjects with at least 6 inflammatory papules and pustules, moderate
to severe facial
erythema and telangiectasia entered the open phase of the study.
Eighty-eight subjects
responded to treatment with systemic tetracycline and topical
metronidazole gel as measured
by at least a 70% reduction in the number of inflammatory lesions.
These subjects were
randomized to receive 1 of 2 treatments: either 0.75% metronidazole
gel or placebo gel.
INTERVENTIONS: Subjects were evaluated monthly for up to 6 months to
determine
relapse rates. MAIN OUTCOME MEASURES: Inflammatory papules and
pustules were
counted at each visit. Relapse was determined by the appearance of a
clinically significant
increase in the number of papules and pustules. Prominence of
telangiectases and dryness
(roughness and scaling) were also observed. RESULTS: In the open
phase, treatment with
tetracycline and metronidazole gel eliminated all papules and pustules
in 67 subjects (59%).
The faces of 104 subjects (92%) displayed fewer papules and pustules
after treatment, and
82 subjects (73%) exhibited less erythema. In the randomized
double-blind phase, the use of
topical metronidazole significantly prolonged the disease-free
interval and minimized
recurrence compared with subjects treated with the vehicle. Eighteen
(42%) of 43 subjects
applying the vehicle experienced relapse, compared with 9 (23%) of 39
subjects applying
metronidazole gel (P<.05). The metronidazole group had fewer papules
and/or pustules after
6 months of treatment (P<.01). Relapse of erythema also occurred less
often in subjects
treated with metronidazole (74% vs 55%). CONCLUSION: In a majority of
subjects
studied, continued treatment with metronidazole gel alone maintains
remission of moderate to
severe rosacea induced by treatment with oral tetracycline and topical
metronidazole gel.
====================================================
11.) Effective sunscreen ingredients and cutaneous irritation in patients with rosacea.
====================================================
Author
Nichols K; Desai N; Lebwohl MG
Address
Department of Dermatology, Mount Sinai School of Medicine, New York,
New York,
USA.
Source
Cutis, 61(5):344-6 1998 Jun
Abstract
Patients with rosacea are particularly susceptible to the irritation
caused by sunscreen
ingredients. The purpose of this bilateral comparison study was to
examine the effects of
different ingredients found in sunscreen on facial cutaneous irritancy
in patients with rosacea.
patients clinically diagnosed with rosacea were asked to test
different preparations of
common sunscreens on their faces. The results show that the presence
or absence of
appropriate protective ingredients, such as dimethicone and
cyclomethicone in the vehicle,
may prevent irritation from other sunscreen ingredients in patients
with inflammatory
conditions such as rosacea.
====================================================
12.) Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea.
====================================================
Author
Neumann E; Frithz A
Address
Department of Dermatology, S¨odersjukhuset, Stockholm, Sweden.
Source
Int J Dermatol, 37(4):263-6 1998 Apr
Abstract
BACKGROUND: Dilatation of vascular vessels in rosacea has generally
been attributed to
yielding to deranged connective tissue. In contrast, in a previous
study a degrading effect of
insufficient vascular vessels in connective tissue has been
demonstrated in connection with
diabetic microangiopathy. In yet another paper, it was demonstrated
that the fusing of
damaged capillaries, which had lost part of their adjacent walls due
to functional inadequacy,
led to the formation of dilated vessels. These pathogenetic patterns
are the main subjects of
this study of rosacea. METHODS: Punch biopsies from rosacea lesions
were examined by
light microscopy and immunochemistry in order to identify structural
changes leading to the
formation of telangiectasias. RESULTS: Deranged connective tissue is
secondary to
damaged capillaries. The primary damage may be evoked mostly by
environmental
influences, mainly the sun. CONCLUSIONS: Infections, infestations, and
granulomatous
formations are not primary in the development of rosacea.
====================================================
13.) Ocular rosacea: patient characteristics and follow-up.
====================================================
Author
Akpek EK; Merchant A; Pinar V; Foster CS
Address
Department of Immunology, Massachusetts Eye and Ear Infirmary, Boston
02114, USA.
Source
Ophthalmology, 104(11):1863-7 1997 Nov
Abstract
PURPOSE: The purpose of this report is to review the presenting
symptoms and signs,
treatment regimens used, complications encountered, and outcome in a
cohort of patients
with ocular rosacea. METHODS: The medical records of 131 patients with
a diagnosis of
ocular rosacea were reviewed retrospectively. Data were entered in a
tabulated form, and a
descriptive analysis was performed. RESULTS: The age range at
presentation was between
23 and 85 years (mean, 56 years). Cutaneous manifestations of rosacea
were present in 112
of the patients at their first visit. The most common presenting
symptoms were foreign body
sensation and burning, and the most common signs were telangiectasia
and irregularity of lid
margins, and meibomian gland dysfunction. Thirteen patients had
decreased visual acuity at
the time of presentation due to corneal complications. Six of these
patients required
penetrating keratoplasty during the course of their disease. Seven
patients had severe
cicatrizing conjunctivitis at the time of referral. One hundred
thirteen patients were treated
with oral tetracycline derivatives. Seven patients were left with
visual acuity less than 20/400,
and one patient underwent enucleation for corneal perforation and
endophthalmitis.
CONCLUSIONS: Ocular rosacea is a common disease involving the skin and
the eyes. It is
widely underdiagnosed by many ophthalmologists despite the blinding
potential. Successful
therapy requires a multidisciplinary approach.
====================================================
14.) Cutaneous angiosarcoma of the face: clinicopathologic and
immunohistochemical study of a case resembling rosacea clinically.
====================================================
Author
Mentzel T; Kutzner H; Wollina U
Address
Institute of Pathology, University of Jena, Germany.
Source
J Am Acad Dermatol, 38(5 Pt 2):837-40 1998 May
Abstract
An unusual cutaneous angiosarcoma resembling rosacea clinically is
described. A
66-year-old man presented with a red discoloration and a diffuse
swelling on his nose over a
2-year period that was diagnosed as rosacea. Despite antiinflammatory
treatment, the
infiltration increased and, after repeated skin biopsies, the
diagnosis of a well-differentiated
cutaneous angiosarcoma associated with a prominent inflammatory
infiltrate was considered.
The neoplasm was treated by surgery. The described case emphasizes
that diffuse swelling
and rosacea-like clinical features should be added to the variably
clinical features of
cutaneous angiosarcoma.
====================================================
15.) A study on Demodex folliculorum in rosacea.
====================================================
Author
Abd-El-Al AM; Bayoumy AM; Abou Salem EA
Address
Department of Dermatology, Faculty of Medicine, Al-Azhar University,
Nasr City, Cairo.
Source
J Egypt Soc Parasitol, 27(1):183-95 1997 Apr
Abstract
A random sample of 16 female patients suffering from papulopustular
rosacea (PPR) as well
as (16) normal female healthy subjects as control group were adopted
in this study to assess
of Demodex folliculorum pathogenesis. It was done through
determination of mite density
using a standard skin surface biopsy 10.5 cm2 from different
designated 6 areas on the face,
and scanning electron microscopic study (SEM) as well as total IgE
estimation. A trial of
treatment using Crotamiton 10% cream with special program was also
attempted. All
subjects ranged between 35-55 years old. All patients with rosacea and
15 of the control
group i.e. 75.93% were found to harbour mites. The mean mite counts by
site distribution
were 28.6 & 6.9 on the cheeks, followed by 14.5 & 3.0 on the forehead
and lastly 6.8 &
0.8 on the chin in PPR and control groups respectively. The total mean
mite count in patients
was 49.9 initially and 7.9 after treatment. In the control group it
was 10.7 & 10.6
respectively. The mean total IgE was 169.4 & 168.4 and 96.3 & 98.4 in
PPR and control
groups respectively Light and scanning electron microscopy revealed
that all mites were
pointing in one direction. Some of them were containing bacteria
inside their gut and on their
skin. After treatment 3 cases (18.75%) were completely cured, 10 cases
(62.5%) gave
moderate response while 3 cases (18.75) have no response. In
conclusion, this study
supports the pathogenic role of D. folliculorum in rosacea.
====================================================
16.) A double-blind, multicenter clinical trial comparing efficacy of
once-daily metronidazole 1 percent cream to vehicle in patients with rosacea.
====================================================
Author
Breneman DL; Stewart D; Hevia O; Hino PD; Drake LA
Address
Dermik Laboratories, Inc., Collegeville, Pennsylvania 19426-1200, USA.
Source
Cutis, 61(1):44-7 1998 Jan
Abstract
The efficacy and safety of a new formulation of metronidazole 1
percent cream applied once
daily was compared to vehicle cream in a double-blind, randomized,
parallel group,
ten-week clinical study. The results showed that metronidazole 1
percent cream was
significantly better than vehicle in reducing the lesions of rosacea,
improving erythema, and
physician's global rosacea scores. The incidence of adverse events
related to the skin was
low.
====================================================
17.) The Demodex mite population in rosacea [see comments]
====================================================
CM - Comment in: J Am Acad Dermatol 1994 May; 30(5 Pt 1):812-3
SO - J Am Acad Dermatol 1993 Mar;28(3):443-8
AU - Bonnar E; Eustace P; Powell FC
AD - University Department of Ophthalmology, Mater Misercordiae Hospital, Dublin, Ireland.
MJ - Acne Rosacea [parasitology]; Mites; Skin [parasitology]
MN - Acne Rosacea [drug therapy]; Adult; Aged, 80 and over; Aged; Face; Middle Age; Tetracycline [therapeutic use]
MT - Animal; Female; Human; Male
PT - JOURNAL ARTICLE
AB - BACKGROUND: The cause of rosacea is unknown; among other factors a causative role has been postulated for the hair follicle mites Demodex folliculorum and Demodex brevis. OBJECTIVE: Our purpose was to compare the population density of Demodex mites in facial skin of defined categories of patients with rosacea with control subjects. We also assessed the impact of tetracycline therapy on the mite population. METHODS: The population density and distribution of Demodex mites were studied in the facial skin of 42 patients with rosacea and 42 age- and sex-matched control subjects. Mites were counted in measured skin surface biopsy specimens obtained from six standard facial sites with cyanoacrylate glue. RESULTS: The mean mite count was 49.8 (range 2 to 158) in patients with rosacea and 10.8 (range up to 97) in control subjects (p 0.001); the highest density of mites was found on the cheeks. A statistically significant increase in mites was found in all subgroups of rosacea, being most marked in those with steroid-induced rosacea. Mite counts in patients with rosacea before and after a 1-month course of oral tetracycline showed no significant difference. CONCLUSION: Increased mites may play a part in the pathogenesis of rosacea by provoking inflammatory or allergic reactions, by mechanical blockage of follicles, or by acting as vectors for microorganisms.
====================================================
18.) Treatment of rosacea: topical clindamycin versus oral tetracycline.
====================================================
SO - Int J Dermatol 1993 Jan;32(1):65-7
AU - Wilkin JK; De Witt S
AD - Department of Medicine, Ohio State University.
MJ - Acne Rosacea [drug therapy]; Clindamycin [analogs & derivatives]; Tetracycline [therapeutic use]
MN - Administration, Cutaneous; Administration, Oral; Adult; Aged; Clindamycin [therapeutic use]; Double-Blind Method; Follow-Up Studies; Middle Age
MT - Comparative Study; Human; Support, Non-U.S. Gov't
PT - CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
AB - BACKGROUND. A new topical antibiotic preparation, clindamycin in a lotion base, was compared with oral tetracycline in the treatment of rosacea. Forty-three patients clinically diagnosed as having rosacea were examined in an investigator-blinded study. METHODS. Patients used topical clindamycin lotion applied twice daily or the usual oral dose of tetracycline hydrochloride (250 mg four times a day for 3 weeks, then 250 mg twice a day for the remaining 9 weeks). Patients' lesions were examined clinically at 3-week intervals over a period of 12 weeks. RESULTS. Topical clindamycin treatment produced similar clinical results to oral tetracycline and was superior in the eradication of pustules. CONCLUSIONS. These results show topical clindamycin in a lotion base to be a safe and effective alternative to oral tetracycline therapy in the treatment of rosacea.
====================================================
19.) [Double-blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea]
====================================================
TT - [Etude en double insu contre excipient du metronidazole gel a 0.75 p. 100 dans le traitement de la rosacee.]
SO - Ann Dermatol Venereol 1993;120(2):129-33
AU - Espagne E; Guillaume JC; Archimbaud A; Baspeyras M; Boitier F; Bussiere M; Chamberlin J; Coin A; Di Crescenzo MC; Dolivo M; et al
AD - Groupe d'Essais Therapeutiques en Pratique de Ville, Hopital Henri Mondor, Creteil.
MJ - Acne Rosacea [drug therapy]; Metronidazole [therapeutic use]
MN - Administration, Topical; Adult; Double-Blind Method; Excipients; Gels; Metronidazole [administration & dosage]; Placebos
MT - Comparative Study; Female; Human; Male
MC - English Abstract
PT - CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
AB - INTRODUCTION. The proven value of tetracyclines and metronidazole administered orally in the treatment of the chronic and recurrent disease that is rosacea is tempered by the important undesirable effects observed in long-term therapy. The purpose of this study was to test the effectiveness of an 0.75 p. 100 metronidazole gel in the treatment of rosacea. PATIENTS AND METHODS. The study involved two groups of patients: one received the metronidazole gel and the other the vehicle of the gel used as placebo. The multicentre randomized trial was conducted in the double-blind fashion by 18 private dermatologists working in the Paris region. Fifty one patients who, since more than 3 months, had been presenting with rosacea, defined as at least 4 papulopustules associated with erythema and/or telangiectasia, entered the trial. Topical treatments and systemic treatments which had shown some activity against rosacea had been interrupted for 15 days or 2 months respectively. The product (or the placebo) was applied a.m. and p.m. on the whole dry face. The patients were seen on days 0, 21 and 42. The evaluation was purely clinical, and the principal criterion of judgement was a change in the number of papulopustules between days 0 and 42. RESULTS. The metronidazole gel reduced the number of papulopustules between day 0 and day 42, and this reduction was significantly greater than that observed with the excipient alone. The active product began to be effective during the third week and remained so during the next three weeks. Both the metronidazole gel and its excipient seemed to be poorly tolerated, with frequent complaints of dry skin, but in 5 women of the metronidazole group this dryness was alleviated by application of moisturizers. CONCLUSION. This study has demonstrated that the 0.75 p. 100 metronidazole gel is effective in the treatment of the papulopustular component of rosacea.
====================================================
20.) Oral spironolactone therapy in male patients with rosacea.
====================================================
SO - J Dermatol 1992 May;19(5):293-7
AU - Aizawa H; Niimura M
AD - Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan.
MJ - Acne Rosacea [drug therapy]; Spironolactone [administration & dosage]
MN - Acne Rosacea [blood]; Administration, Oral; Adult; Middle Age; Sebaceous Glands [drug effects]; Sex Hormones [blood]; Spironolactone [pharmacology]
MT - Human; Male
PT - JOURNAL ARTICLE
AB - Spironolactone at 50 mg/day was orally administered for four weeks to 13 male patients with rosacea in order to observe its clinical effectiveness. Serum estradiol (E2), 17OH-progesterone (17OH-P4), testosterone (T), androstenedione (delta 4 A), dihydrotestosterone (DHT), dehydro-epiandrosterone sulfate (DHEA-S) were measured prior to and after treatment. Although there were no significant changes in T, delta 4A, DHT, or DHEA-S, the serum levels of 17OH-P4 increased significantly. E2 tended to increase, although the change was not significant. Two of the 13 patients discontinued spironolactone treatment because of general malaise, but seven of the remaining eleven patients exhibited an improvement in their rosacea. These findings demonstrate that a low dose of spironolactone is effective in the treatment of rosacea in some male patients and suggest that it is possible that changes in the metabolism of sex steroid hormones such as cytochrome p-450 isozymes have some bearing on the etiology of rosacea.
====================================================
21.) Childhood rosacea.
====================================================
SO - Pediatr Dermatol 1992 Mar;9(1):22-6
AU - Drolet B; Paller AS
AD - Department of Pediatrics and Dermatology, Children's Memorial Hospital, Northwestern University Medical School, Chicago, Illinois.
MJ - Acne Rosacea
MN - Acne Rosacea [diagnosis] [drug therapy]; Antibiotics [therapeutic use]; Child
MT - Case Report; Female; Human; Male
PT - JOURNAL ARTICLE
AB - Rosacea usually occurs in adults and rarely has been noted in children. We recently observed three children with rosacea, all of whom responded dramatically to systemic and topical antibiotics. Rosacea in childhood must be distinguished from other erythematous facial disorders, most commonly acne, granulomatous perioral dermatitis, and sarcoidosis. The distribution of facial lesions; the presence of telangiectasias, flushing, and pustules; and the appearance of lesional biopsy sections and the ocular lesions, if present, allow differentiation of rosacea from other facial eruptions.
====================================================
22.) A clinical and histopathologic study of granulomatous rosacea.
====================================================
SO - J Am Acad Dermatol 1991 Dec;25(6 Pt 1):1038-43
AU - Helm KF; Menz J; Gibson LE; Dicken CH
AD - Department of Dermatology, Mayo Clinic, Rochester, MN 55905.
MJ - Acne Rosacea [pathology]
MN - Acne Rosacea [drug therapy]; Aged, 80 and over; Aged; Blister [pathology]; Elastic Tissue [pathology]; Erythema [pathology]; Folliculitis [pathology]; Granuloma [drug therapy] [pathology]; Histiocytes [pathology]; Lymphocytes [pathology]; Middle Age; Retrospective Studies; Single-Blind Method; Skin Aging [pathology]; Skin [blood supply] [pathology]; Telangiectasis [pathology]
MT - Female; Human; Male
PT - JOURNAL ARTICLE
AB - A retrospective clinical and histopathologic study of 53 patients with granulomatous rosacea was undertaken. The patients had a broad clinical spectrum of lesions that ranged from primarily erythema to papulonodular lesions. Extrafacial lesions occurred in 15% of patients. Histologic examination showed mixed lymphohistiocytic inflammation (primarily lymphocytic inflammation in 40% of patients and primarily histiocytic with a few giant cells in 34%), epithelioid granulomas in 11% of patients, and epithelioid granulomas with caseation necrosis in 11%. Most patients had a good response to oral antibiotic therapy. Granulomatous rosacea is not a distinct disease but can be regarded and treated as a subtype of rosacea.
====================================================
23.) Flash lamp pumped dye laser for rosacea-associated telangiectasia and erythema.
====================================================
SO - J Dermatol Surg Oncol 1991 Jun;17(6):522-5
AU - Lowe NJ; Behr KL; Fitzpatrick R; Goldman M; Ruiz-Esparza J
MJ - Acne Rosacea [complications]; Erythema [surgery]; Laser Surgery; Telangiectasis [surgery]
MN - Adult; Aged; Erythema [etiology]; Middle Age; Prognosis; Telangiectasis [etiology]
MT - Female; Human; Male
PT - JOURNAL ARTICLE
AB - The persistence of facial telangiectasis and erythema in patients with rosacea frequently presents a major cosmetic problem. It may also contribute to relapses of papular and pustular lesions. This study of 27 patients treated for their telangiectasia and erythema with a flash lamp pumped dye laser tuned at 585 nm is described. The laser gave good or excellent reduction of telangiectasia and erythema and overall appearance in 24 of the patients with between one and three treatments. In addition, papule and pustule activity was decreased in 59.2% of the patients, with those with the most severe pre-treatment activity having the most significant improvement. It is suggested that this is a useful additional form of treatment that may improve the telangiectasia and erythematous component of rosacea.
====================================================
24.) Topical metronidazole for severe and recalcitrant rosacea: a prospective open trial.
====================================================
SO - Cutis 1989 Mar;43(3):283-6
AU - Lowe NJ; Henderson T; Millikan LE; Smith S; Turk K; Parker F
AD - Department of Dermatology, UCLA School of Medicine.
MJ - Acne Rosacea [drug therapy]; Metronidazole [administration & dosage]
MN - Administration, Topical; Adult; Aged; Clinical Trials; Facial Dermatoses [drug therapy]; Middle Age; Prospective Studies
MT - Female; Human; Male; Support, Non-U.S. Gov't
PT - CLINICAL TRIAL; JOURNAL ARTICLE
AB - Nineteen patients with severe or recalcitrant rosacea were treated twice daily with 0.75 percent metronidazole topical gel in an open label study. Sixteen of the patients (84 percent) showed 50 percent or greater reduction in inflammatory lesions, while fifteen (79 percent) demonstrated a reduction in erythema severity and an improvement when evaluated by the investigator global assessment. No positive response was recorded for any patient prior to topical medication, whereas six of nine patients previously treated with tetracycline/minocycline demonstrated improvement. Seven of these nine patients responded to topical metronidazole treatment. One additional patient who did not respond to minocycline or desonide treatment showed a good response to topical metronidazole. Only one patient reported local irritation after using metronidazole. These results demonstrate that topical metronidazole gel is safe and effective for the treatment of severe or recalcitrant rosacea.
====================================================
25.) An epidemiological study of rosacea.
====================================================
SO - Acta Derm Venereol 1989;69(5):419-23
AU - Berg M; Liden S
AD - Department of Dermatology, Karolinska Sjukhuset, Stockholm, Sweden.
MJ - Acne Rosacea [epidemiology]; Facial Dermatoses [epidemiology]
MN - Acne Rosacea [classification]; Adult; Facial Dermatoses [classification]; Middle Age; Sweden
MT - Female; Human; Male; Support, Non-U.S. Gov't
PT - JOURNAL ARTICLE
AB - In a non-selected population of 809 office employees (454 women and 355 men) 81 persons were diagnosed as having rosacea, giving a prevalence of 10% (women 14%, men 5%). The rosacea group was compared with the rest of the study population. Most of the cases were rather mild. The rosacea was of an erythematotelangiectatic type in 81% of the cases and of a papulopustular type in 19%. Unilateral lesions were found in 11 subjects (14%). Only 17% of those with rosacea were impaired by sunlight, whereas 26% improved. In the rosacea group, 27% were found to suffer from migraine and 42% from a tendency to flush, compared with 13% (p less than 0.001) and 16% (p less than 0.001) respectively in the comparison group. Flushing and the regulatory mechanism of the blood vessels thus seem to be of importance in the pathogenesis of rosacea. Individuals with good pigmentation ability showed a tendency to a decreased occurrence of rosacea. The frequency of eye complaints was the same in the two groups.
====================================================
26.) Isotretinoin treatment of rosacea.
====================================================
SO - Acta Derm Venereol 1987;67(1):89-91
AU - Turjanmaa K; Reunala T
MJ - Acne Rosacea [drug therapy]; Tretinoin [therapeutic use]
MN - Adult; Aged; Follow-Up Studies; Isomerism; Middle Age; Nasal Mucosa [drug effects]; Recurrence; Time Factors; Tretinoin [adverse effects]; Xerostomia [chemically induced]
MT - Female; Human; Male
PT - JOURNAL ARTICLE
AB - Twenty patients with severe rosacea were treated with isotretinoin for 3-6 months. Six patients initially received 1.0 mg/kg and 14 patients 0.5 mg/kg of isotretinoin. The response was good or excellent in all patients and the papulopustular lesions in particular cleared promptly. Patients receiving 1.0 mg/kg of isotretinoin experienced more side-effects and the dose had to be lowered in five of the six patients. Seventeen of the 20 patients had no relapses during a follow-up of one year showing that isotretinoin has a long-lasting favourable effect in rosacea.
====================================================
27.) May Helicobacter pylori be important for dermatologists?
====================================================
AU: Rebora-A; Drago-F; Parodi-A
AD: Department of Dermatology, University of Genoa, Italy.
SO: Dermatology. 1995; 191(1): 6-8
ISSN: 1018-8665
PY: 1995
LA: ENGLISH
CP: SWITZERLAND
AB: Helicobacter pylori, a microaerophilic gram-negative bacterium, is the major cause of gastritis, plays a key role in the etiology of peptic ulcer and is a risk factor for gastric cancer. Although 50% of the population is affected, dermatologist seem to be unaware of the impact H. pylori may have on cutaneous pathology. Among skin diseases, H. pylori has been related so far only with chronic urticaria and rosacea. In rosacea, histology of the stomach mucosa revealed tht 84% of 31 patients were H. pylori positive. Twenty percent of them were serologically negative, but, overall, 100% of the 20 patients with both histology and serology were H. pylori positive with either test. The consistency between clinical success with metronidazole and abatement of H. pylori isolates and serology after treatment was an additional evidence suggesting an etiologic relationship between rosacea and H. pylori infection. Rosacea has often been linked with gastrointestinal disturbances. H. pylori, therefore, may link them to the well-known beneficial activity of metronidazole on rosacea lesions. The role of H. pylori is more probable in erythrotic rosacea than in its papulopustular and granulomatous stages. As in Bacillus subtilis intoxication, a flush-inducing toxin cannot be excluded. Despite the difficulty to find patients accepting bioptic gastroscopies, large case-control studies should be done before a causal relationship with urticaria and rosacea is firmly established.
====================================================
28.) Efficacy and safety of topical azelaic acid (20 percent cream): an overview of
results from European clinical trials and experimental reports.
====================================================
AU: Graupe-K; Cunliffe-WJ; Gollnick-HP; Zaumseil-RP
AD: Department of Clinical Development, Schering AG, Berlin, Germany.
SO: Cutis. 1996 Jan; 57(1 Suppl): 20-35
ISSN: 0011-4162
PY: 1996
LA: ENGLISH
CP: UNITED-STATES
AB: Azelaic acid cream (20 percent) is a new topical treatment for acne with an additional therapeutic potential in rosacea and hyperpigmentation disorders. Azelaic acid (AzA; HOOC-(CH2)7-COOH) is a naturally occurring compound that interferes with acne pathogenesis by virtue of its antikeratinizing, antibacterial, and anti-inflammatory properties. Vehicle-controlled studies have verified that AzA exercises a significant and clinically relevant effect on both non-inflammatory and inflammatory acne lesions. Comparisons with clinically proven therapies have shown that 20 percent AzA cream is an effective monotherapy in mild to moderate forms of acne, with an overall efficacy comparable to that of tretinoin (0.05 percent), benzoyl peroxide (5 percent), and topical erythromycin (2 percent). In the treatment of moderate to severe acne, 20 percent AzA cream may be favorably combined with minocycline (90 percent good and excellent results), and may contribute towards reducing recurrences following discontinuation of systemic therapy (maintenance therapy with AzA cream). Particular advantages of AzA therapy include its favorable safety and side effect profile. It is non-teratogenic, is not associated with systemic adverse events or photodynamic reactions, exhibits excellent local tolerability, and does not induce resistance in Propionibacterium acnes.
====================================================
29.) Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with
doxycycline [see comments]
====================================================
Quarterman MJ; Johnson DW; Abele DC; Lesher JL Jr; Hull DS; Davis LS
Department of Medicine, Medical College of Georgia, Augusta, USA.
Arch Dermatol (UNITED STATES) Jan 1997 133 (1) p49-54 ISSN: 0003-987X
Note: Comment in: Arch Dermatol 1997 Jan;133(1 ):89-90
Language: ENGLISH
Document Type: CLINICAL TRIAL; JOURNAL ARTICLE
Journal Announcement: 9705
Subfile: AIM; INDEX MEDICUS
OBJECTIVE: To examine ocular signs, symptoms, and results of tear analysis in
patients with cutaneous rosacea before, during, and after doxycycline therapy.
DESIGN: Before-after trial. SETTING: General community. PATIENTS OR OTHER
PARTICIPANTS: Thirty-nine patients with cutaneous rosacea underwent dermatologic and
ocular examinations, testing of tear break-up time, and Schirmer testing at baseline
and 4, 8, and 12 weeks. Six patients did not complete the study. Baseline tear
break-up time and results of Schirmer test were compared with those of 13 patients
without rosacea who were matched for age and sex. INTERVENTION: Patients with
rosacea were given doxycycline, 100 mg daily for 12 weeks. MAIN OUTCOME MEASURE:
Statistically significant (P, .05) improvement in tear break-up time. RESULT: The
most frequent ocular symptoms were dryness, itching, blurred vision, and
photosensitivity, all of which improved significantly with treatment. All patients
had signs of ocular disease, most commonly erythema and telangiectasia, meibomian
gland dysfunction, and ciliary base injection. Significant improvement (P,.05) for
scales, erythema and telangiectasia, ciliary base injection, bulbar injection,
papillary hypertrophy, and punctate epithelial erosions was seen. Average tear break-
up time for the patients with rosacea was 5.7 seconds, which improved to 10.8 seconds
after 12 weeks of treatment (P = .007). Baseline tear break-up time was
significantly lower than for the comparison group of normal subjects (P = .001).
There was no correlation between severity of cutaneous disease and ocular disease.
CONCLUSIONS: All patients with cutaneous rosacea had some degree of ocular
involvement. Tear break-up time is abnormal in patients with rosacea. Ocular
erythema and telangiectasia, meibomian gland dysfunction, and short tear break-up
time in patients with cutaneous rosacea are indicators of ocular rosacea.
Doxycycline, 100 mg daily, will improve ocular disease and increase the tear break-up
time.
====================================================
30.) [Dapsone in granulomatous rosacea]
Dapson bei granulomatoser Rosazea.
====================================================
Krause MH; Torricelli R; Kundig T; Trueb RM; Hafner J
Dermatologische Klinik und Poliklinik, Universitatsspital, Zurich.
Hautarzt (GERMANY) Apr 1997 48 (4) p246-8 ISSN: 0017-8470
Language: GERMAN Summary Language: ENGLISH
Document Type:
JOURNAL ARTICLE English Abstract
Journal Announcement: 9709
Subfile: INDEX MEDICUS
We report on two patients with granulomatous rosacea and another patient with
granulomatous perioral dermatitis who responded well to dapsone. Dapsone has a
pharmacological double function as both an antibiotic and an antiphlogistic drug.
Before the introduction of isotretinoin, dapsone had its place in the treatment of
severe acne. To date, its use in granulomatous rosacea has not been described. When
hematologic parameters are monitored, dapsone is considered a safe and cost-effective
drug, especially in countries where isotretinoin is not readily available. However,
the definite value of dapsone in granulomatous rosacea should be established by a
controlled study.
====================================================
31.) Noritate Available For Treatment Of Rosacea
====================================================
NEW YORK, NY -- January 22, 1998 -- Dermik Laboratories, Inc., has
announced the availability of Noritate(TM) (metronidazole cream) Cream, 1%,
the first prescription topical rosacea therapy cleared for once-daily dosing in
the treatment of inflammatory lesions and erythema (facial redness) associated
with the condition.
Cleared for marketing by the United States Food and Drug Administration
(FDA), this new treatment has been shown in studies to significantly reduce
inflammatory lesions of rosacea in as little as four weeks with minimal skin
dryness and irritation at the site of application. Rosacea is a chronic,
inflammatory skin disorder that affects an estimated 13 million Americans.
"The rapid efficacy, unique approval for once-a-day dosing and erythema
indication make Noritate an exciting new therapeutic option for patients with
rosacea," said Joseph Jorizzo, MD, chair of the department of dermatology,
Wake Forest University School of Medicine, who conducted clinical studies on
the product. "The once-daily dosage, in particular, is a major benefit that offers
an exciting opportunity that may improve patient compliance."
Rosacea therapies should become part of a patient's daily routine and be
consistently followed in order to manage the condition. According to Dr.
Jorizzo, daily regimens that are difficult to follow, time consuming or
inconvenient, may prevent patients from complying with their treatment.
"Compliance has been a significant problem in treating rosacea," Dr. Jorizzo
said. "Patients are often reluctant to commit to complex treatment programs
and want a simplified routine."
Rosacea is a condition characterized by excessive redness and accompanied
by papules and pustules on the cheeks, chin, nose and forehead. Often
mistaken for acne, rosacea is most prevalent among fair-skinned women
between the ages of 30 and 50, but tends to be more severe when present in
men. It is frequently triggered or exacerbated by extreme temperatures, spicy
foods, alcoholic beverages, exercise and stress. The often embarrassing
condition rarely reverses itself and cannot be cured, but it can be controlled
with regular treatment.
Most of the 13 million Americans affected by rosacea are women, and many
who suffer from the condition may be concerned about their appearance
because of the unpredictable and unsightly flushing.
====================================================
32.) Lotion Proven Safe, Effective For Rosacea
====================================================
LINCOLNSHIRE, Ill., June 5, 1997 -- A topical lotion used successfully for
years to treat acne has recently been proven effective and safe for treating
rosacea, a chronic skin disease. The study appears in the June issue of Journal
of Dermatological Treatment.
Rosacea is a chronic skin disease characterized by facial redness affecting the
nose, cheeks and chin. Approximately five percent of the U.S. population suffer
from the disease, which has disfigured the noses of individuals such as W.C.
Fields and J.P. Morgan.
"This study verifies what a growing number of dermatologists and other
physicians already know," says Scott B. Phillips, M.D., principal author of the
study. "The combination of sodium sulfacetamide and sulfur is a safe and
effective treatment for rosacea." Dr. Phillips is a dermatologist and clinical
assistant professor at the University of Chicago Hospitals.
Sodium sulfacetamide and sulfur are ingredients found in Novacet(R) Lotion
(sodium sulfacetamide 10 percent and sulfur 5 percent), a prescription
medication approved for the treatment of acne from GenDerm Corporation.
The vehicle controlled, double-blind study tested 103 patients suffering from
rosacea. Patients who used Novacet showed significant improvement with an
83 percent reduction in erythema (facial redness) and 78 percent decrease in
inflammatory lesions by the eighth week of the study.
Rosacea typically appears after age 30 and affects more women than men. In
the early stages of the disease, facial flushing or blushing will appear and
disappear. As the disease progresses, small red or pus-filled bumps appear.
These "bumps" are often mistaken for acne. For some individuals, the nose and
cheeks may appear puffy, and thick, knobby bumps may develop on the nose.
While there is no cure for rosacea, it can be controlled with early medical
treatment and lifestyle modification, such as avoiding spicy foods, reducing
one's stress, or not spending extended periods of time under the hot sun.
A variety of prescription medications are available for treating rosacea. These
include the use of oral and topical antibiotics, topical sulfur medications, laser
treatments or surgery.
For information about a free brochure called "Rosacea: The More You
Know...," people can call toll-free by dialing 888-278-4545. Or write to
Rosacea Help Line, 600 Knightsbridge Parkway, Lincolnshire, Illinois 60069.
======================================================================
DATA-MEDICOS/DERMAGIC-EXPRESS No.(14) 06/11/98 DR. JOSE LAPENTA R. DERMATOLOGO
======================================================================
Dr. Jose Lapenta R.
Maracay, Venezuela
[email protected]
|
